Skip to content

Acceptability and Tolerability of Ketone Supplements and Effects of BHB Concentrations in Young Adults

Acceptability and Tolerability of Ketone Supplements and Their Effects on Capillary Beta-hydroxybutyrate Concentrations in Young Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05390385
Enrollment
14
Registered
2022-05-25
Start date
2022-09-23
Completion date
2023-08-15
Last updated
2023-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exogenous Ketosis

Keywords

exogenous ketones, ketone supplementation, ketone monoester, ketone salt, tolerability, acceptability, beta-hydroxybutyrate

Brief summary

Assess the acceptability and tolerability of two different commercially available ketone supplements and determine their effects on capillary blood concentrations of the ketone beta-hydroxybutyrate and glucose in young adults.

Detailed description

Past findings suggest that raising ketone concentrations through the use of a ketogenic diet (high-fat, moderate-protein, low-carbohydrate) is effective for preventing weight gain and decreasing appetite. However, strict adherence to this diet is difficult, and ending the diet can result in the regaining of body weight. Our group has investigated the effects of various ketone supplements in both rodents and humans. Past results of our group and that of our colleagues suggest that ketone supplements have the ability to increase ketone concentrations in the blood, decrease appetite, lower body weight, and maintain lean body mass. Exogenous ketones may serve as an alternative to the ketogenic diet by increasing concentrations of ketones without the need for adherence to a strict diet. However, little is known about ketone supplements as it relates to their tolerability and efficacy. For example, the taste of these supplements is unacceptable to some individuals and it is unclear if ketone supplements provide an adequate approach to raise and maintain circulating ketone concentrations as observed with the ketogenic diet. This information will be valuable before launching larger-scale human trials. Ketone supplements (KE1 and KE4) will be obtained from KetoneAid (Falls Church, VA). Participants will be asked to drink (5g and 10g) of each supplement separated by at least 3 days. Capillary blood samples will be measured using a handheld device to measure circulating beta-hydroxybutyrate (BHB) and glucose concentrations while a questionnaire will be used to assess the acceptability and tolerability of the ketone supplements.

Interventions

DIETARY_SUPPLEMENTKE1 5g

5g of KE1 (KetoneAid, Falls Church, VA), diluted to 4 ounces

DIETARY_SUPPLEMENTKE1 10g

10g of KE1 (KetoneAid, Falls Church, VA), equal to 4 ounces

DIETARY_SUPPLEMENTKE4 5g

5g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces

DIETARY_SUPPLEMENTKE 10g

10g of KE4 (KetoneAid, Falls Church, VA), diluted to 4 ounces

OTHERPlacebo drink

Flavor-matched control placebo drink (KetoneAid, Falls Church, VA), 4 ounces

Sponsors

University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

Supplement packaging will be labeled with an alphanumeric code that is only understood by an individual who is not involved in the study. The participants and study team will both be blinded to the supplement being given.

Intervention model description

Participants will each undergo all five treatments, in randomized order. The five treatments include the control placebo, 5g of KE1, 10g of KE1, 5g of KE4, and 10g of KE4. There will be a minimum of two days washout period between treatments.

Eligibility

Sex/Gender
ALL
Age
18 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult 18-25 years of age * In generally good health * Able and willing to attend study visits (once every 3 days for \ 2 weeks) * BMI 18.5-29.9

Exclusion criteria

* Pregnant * Has preexisting medical conditions, including Type 2 diabetes, heart disease, or cancer * BMI ≥ 30

Design outcomes

Primary

MeasureTime frameDescription
Supplement tolerability and acceptability2 hoursThe ketone supplements being used have been described as having strong, disagreeable flavors. Therefore, the first outcome measure will be understanding how the flavors and gastrointestinal effects of both supplements may impact subjects. This outcome measure will be assessed by measuring the symptoms experienced, the time at which each symptom occurred, and the duration of each symptom using a scaled symptom questionnaire titled Symptom Questionnaire. The questionnaire rates symptoms on an ordinal scale from absent, mild, moderate, to severe, with absent being the minimum value and better outcome, and severe being the maximum value and worst outcome. The questionnaire will assess the time that each symptom occurred, on a scale from immediately, one hour, and two hours after supplement consumption. The questionnaire will assess the duration of each symptom, on a scale of less than thirty minutes, one hour, and two hours after each symptom occurred.
Capillary beta-hydroxybutyrate concentrations2 hoursExogenous ketone supplements are now widely available at the commercial level, so it is important to understand the concentration-dependent effects of these supplements on circulating ketone concentrations, measured by concentrations of beta-hydroxybutyrate following a capillary blood fingerstick.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026